A Benefit and the Prospects of IL-6 Inhibitors in Idiopathic Multicentric Castleman's Disease
Modern Rheumatology - United Kingdom
doi 10.1080/14397595.2018.1532383
Full Text
Open PDFAbstract
Available in full text
Date
January 14, 2019
Authors
Publisher
Informa UK Limited